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Abstract
Background: Intestinal parasitic nematode diseases are one of the great diseases of our time. Intestinal roundworm
parasites, including hookworms, whipworms, and Ascaris, infect well over 1 billion people and cause significant morbidity,
especially in children and pregnant women. To date, there is only one drug, albendazole, with adequate efficacy against
these parasites to be used in mass drug administration, although tribendimidine may emerge as a second. Given the
hundreds of millions of people to be treated, the threat of parasite resistance, and the inadequacy of current treatments,
new anthelmintics are urgently needed. Bacillus thuringiensis (Bt) crystal (Cry) proteins are the most common used
biologically produced insecticides in the world and are considered non-toxic to vertebrates.
Methods/Principal Findings: Here we study the ability of a nematicidal Cry protein, Cry5B, to effect a cure in mice of a
chronic roundworm infection caused by the natural intestinal parasite, Heligmosomoides bakeri (formerly polygyrus). We
show that Cry5B produced from either of two Bt strains can act as an anthelmintic in vivo when administered as a single
dose, achieving a ,98% reduction in parasite egg production and ,70% reduction in worm burdens when delivered per os
at ,700 nmoles/kg (90–100 mg/kg). Furthermore, our data, combined with the findings of others, suggest that the relative
efficacy of Cry5B is either comparable or superior to current anthelmintics. We also demonstrate that Cry5B is likely to be
degraded quite rapidly in the stomach, suggesting that the actual dose reaching the parasites is very small.
Conclusions/Significance: This study indicates that Bt Cry proteins such as Cry5B have excellent anthelmintic properties in
vivo and that proper formulation of the protein is likely to reveal a superior anthelmintic.
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Introduction
Neglected tropical diseases (NTDs) have a worldwide devastating
impact on the lives of billions of people. Helminth infections
comprise approximately85%oftheNTDburden[1].Thetopthree
ailments on this list of NTDs are all caused by intestinal nematodes
[2]. These infections consist of ascariasis (caused by Ascaris
lumbricoides), trichuriasis (caused by Trichuris trichiura or whipworm),
and hookworm disease (caused by Necator americanus and Ancylostoma
duodenale).Approximately807-1,221millionpeopleareafflictedwith
ascariasis, 604–795 million with trichuriasis, and 576–740 million
with hookworm infections [3]. The widespread and detrimental
effects of parasitic worm infections on human growth, nutrition,
cognition, school attendance and performance, earnings, and
pregnancy have been well documented [2,3]. These infections also
contribute to increased severity/infectivity of HIV/AIDS, malaria,
and tuberculosis due to compromised immune responses [3,4].
Furthermore, parasitic nematode infections confound vaccination
efficacy [5,6]. Despite the high prevalence and destructive nature of
these infections, there are few treatment options. Although four
anthelmintics (levamisole/pyrantel and mebendazole/albendazole)
are approved by the World Health Organization for use in humans,
one, albendazole, is generally preferred in a single-dose regimen
over the others since it is relatively more effective against
hookworms and whipworms [7,8]. However, resistance to albenda-
zole may already be appearing [9,10]. Furthermore, the reliance
upon one compound for treating hundreds of millions of people will
have devastating consequences if widespread resistance ever
becomes a reality. Tribendimidine, developed by the Chinese
CentersforDiseaseControlandPrevention,isemergingasa second
anthelminticwith efficacy similar toalbendazole,butis a member of
the levamisole/pyrantel class to which resistance in human
populations has been reported [11,12,13]. Furthermore, none of
the compounds have been shown to be totally effective against all
helminth infections [8]. Consequently, there is an urgent need for
efficacious, safe, inexpensive, single-dose anthelmintics with new
mechanisms of action.
This search for new anthelmintics has led to examination of
Bacillus thuringiensis (Bt) crystal (Cry) proteins. These proteins are the
most extensively used biologically-produced insecticides in the
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during sporulation. These inclusions contain Cry proteins that are
highlytoxictosomeinvertebratesbutnontoxictohumansandother
vertebrates [15]. The high efficacy against insects, absence of
toxicity towards vertebrates, and low production cost of these
proteins has led to their widespread use in pesticides and in
transgenic crops [14]. So far, three Bt Cry proteins toxic to a broad
range of free-living nematodes and the free-living form of at least
one intestinal parasitic nematode have been discovered, including:
Cry5B, Cry14A, and Cry21A [16]. Cry13A may also have anti-
nematode activity [17]. To date, only one of these, Cry5B, has been
shown to be therapeutic in vivo with activity against intestinal
hookworm parasite (Ancylostoma ceylanicum) infections in hamsters
when delivered daily, per os, over the course of three days [18].
These studies suggest that Cry proteins could provide therapy
for intestinal nematode infections. However, it remains to be
shown that Cry5B can effect a cure against more than A. ceylanicum
infections in hamsters or that Cry proteins are efficacious as single-
dose anthelmintics. Heligmosomoides bakeri (formerly known as
Heligmosomoides polygyrus and Nematospiroides dubius) is one of the
most widely studied rodent intestinal parasite nematodes [19,20].
The nematode has a high infection rate and is the best model for
chronic intestinal nematode infections in immunocompetent mice.
H. bakeri has also played a key role in the history of anthelmintic
development via its use in the discovery of ivermectin [21]. In
addition, H. bakeri infections in mice are a naturally occurring
infection, unlike A. ceylanicum infections in hamsters. Thus, curative
experiments in H. bakeri are complementary to those in A.
ceylanicum, yielding important information as to how Cry proteins
may fare against a broad range of natural intestinal parasites in
vivo. Herein, we report our investigations into single-dose Cry5B
therapy against H. bakeri.
Methods
Animals
Female Swiss Webster white mice were purchased from Harlan
Laboratories and were infected at approximately 6 weeks of age at
an average weight of 25g. Mice were provided with food and water
ad libitum.). This research was approved by the UCSD Institutional
Animal Care and Use Committee (IACUC), protocol number
S08140. The maintenance and care of experimental animals
complied with the University of California’s Animal Care
Program’s guidelines for the humane use of laboratory animals.
Preparation of Bt strains
Crystal-deficient Bt strains HD1 and 4Q7 were transformed
with a plasmid containing the Cry5B gene [23]. Bacillus thuringiensis
subspecies kurstaki HD1-4D8 was ordered through the Bacillus
Genetic Stock Center. Spore lysates (SLs; HD1 and 4Q7 Cry-
deficient strains) and spore-crystal lysates (SCLs; HD1 and 4Q7
transformed with Cry5B plasmid) were prepared using standard
methods and then stored at 280u [23]. Bioactivity of SCLs was
confirmed against Caenorhabditis elegans by a mortality assay over
24 h at 25uC. SLs (Cry-minus) were confirmed to lack toxicity
against C. elegans. On the day of use, SL and Cry5B SCL aliquots
were thawed and centrifuged at 4,500 rpm for 15 minutes at 4uC
and the supernatant was removed. The pellet was then
resuspended in distilled water to a final concentration of
2.5 mg/mL, for the HD1 strain, and 2.25 mg/mL, for the 4Q7
strain (protein concentrations were determined by comparing
Cry5B band intensities for four different aliquots of SCLs to
known amounts of bovine serum albumin on Coomassie-stained
8% SDS polyacrylamide protein gels). The placebo SL control
strains were concentrated to the same extent. The samples were
kept on ice until gavage.
Cry5B curative experiments
On day 0, mice were infected per os with a suspension of 200610
H. bakeri L3 larvae in 0.1 mL of distilled water. Larvae were
counted under the microscope, then drawn into a pipette tip and
placed into separate glass test tubes until gavage with a blunt-
ended syringe. On days 14, 16, 18, and 20 post-infection (P.I.),
fecal samples were collected from the mice. Mice were placed
individually in empty plastic cages for 1 h each morning, and the
fecal pellets were collected into 50 mL centrifuge tubes. The
number of eggs present was counted using the modified McMaster
technique [22]. Briefly, feces collected from mice were weighed
and resuspended in a 1 g:15 mL volume of water. The pellets were
allowed to soak overnight before being broken up for 1 h via heavy
vortexing. The eggs were counted using a 2-chamber McMaster
slide, each chamber holding a 0.6 mL volume of a 1:1 mixture of
fecal slurry and saturated sucrose solution. The number of eggs per
gram of feces was thus calculated from the following equation:
number of eggs counted x (1/0.3 mL slurry) x (15 mL slurry/g
feces). For each mouse and each time point, three different egg
counts were made and then averaged.
Each mouse was treated per os on day 15 P.I. with 0.1 mL of
relevant treatment (placebo or Cry protein) through a blunt-ended
syringe. All mice were killed by exposure to CO2 on day 20 P.I.
and the intestines were removed in their entirety. These were
opened longitudinally with a pair of blunt-ended dissecting scissors
and then placed into a 50 mL centrifuge tube with 10–20 mL of
pre-warmed (37uC) PBS for approximately 1 h to allow worms to
dislodge from the intestine. The solution and intestine were
examined under a microscope, using fine tweezers when necessary
for further extrication of worms from the intestine, for determi-
nation of final worm burden.
Tribendimidine curative experiments
Tribendimidine was kindly provided by Dr. Shu-Hua Xiao at
the Chinese Centers for Disease Control and Prevention. The
Author Summary
Intestinal parasitic nematode diseases infect over one
billion people and cause significant disease burden in
children (growth and cognitive stunting, malnutrition), in
pregnant women, and via their dampening of the immune
system in infected individuals. In over thirty years, no new
classes of anti-roundworm drugs (anthelmintics) for
treating humans have been developed. Because of
limitations of the current drugs and the threat of parasite
resistance, new anthelmintics are needed. The soil
bacterium Bacillus thuringiensis (Bt) produces crystal (Cry)
proteins that specifically target and kill insects and
nematodes and is used around the world as a safe
insecticide. Here we test the effects of the Bt Cry protein
Cry5B on a chronic, natural intestinal roundworm infection
in mice, namely the helminth parasite Heligmosomoides
bakeri. We find that a single dose of Cry5B can eliminate
70% of the parasites and can almost completely block the
ability of the parasites to produce progeny. Comparisons
of Cry5B’s efficacy with known anthelmintics suggest its
activity is as good as or perhaps even better than those
currently used. Furthermore, this protein is rapidly
digested by simulated stomach juices, suggesting that
protecting it from these juices would reveal a superior
anthelmintic.
Bt Cry5B as a Single-Dose Anthelmintic
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per os on day 15 P.I. in a total volume of 0.1 mL as per Cry5B
experiments. For these curative experiments, the mice were
infected with on average 150 L3 larvae (six/group except for
placebo group, which only had five mice). Placebo control for
these experiments was 0.1 mL of buffer only.
Digestive fluids for Cry5B metabolic fate studies
Simulated gastric fluid (SGF) was prepared freshly as described
in the United States Pharmacopeia and stored at 4u until use [24].
Cry5B SLC was added to a 1 mL solution of SGF for a final
concentration of 2.5 mg/mL and incubated at 37uC [25]. 50 mL
aliquots of the digestion stock were removed at each time point as
the digestion solution was agitated. Each aliquot was immediately
quenched by neutralization with 15 mL of 0.2 M sodium
carbonate per 50 mL of SGF [25]. Quenched samples were kept
on ice until 2x SDS-PAGE loading buffer was added to each
sample. Mixtures were then heated for 5 min in boiling water and
stored at 220uC until analysis.
Statistical analysis
Data analysis of intestinal worm burdens and fecal egg counts
was carried out and plotted using Prism 5 (GraphPad Software
Inc., La Jolla, CA, U.S.A.). For worm burdens, average indicates
the average worm burdens amongst all the mice in each treatment
group. For fecal egg counts, average indicates the egg count per
mouse averaged from all mice in the group at a given time point.
Fecal egg count data was analyzed via pair-wise comparisons
between groups and days through two-way analysis of variance
(ANOVA) with repeated measures and Bonferroni post tests.
Results were as follows: FTreatment=70.69, degrees of freedom
(df)=1, P,0.0001; FTime=5.241, df=3, P=0.003; FInteraction
=11.43, df=1,3, P,0.0001. Worm burdens for Cry5B treatment
versus placebo were compared using Mann-Whitney U test (one-
tailed). Values are as follows: U=7.5, P=0.0007 for HD1 Cry5B
versus placebo; U=2.0, P=0.0012 for 4Q7 Cry5B versus
placebo. Worm burdens for tribendimidine experiment were
compared using one-way ANOVA and Tukey’s Multiple Com-
parison Test (F=9.387, df=3, 19, P=0.0005).
Results
A single dose of Cry5B is able to achieve a significant
therapeutic effect against H. bakeri parasites in vivo
To determine if Cry5B could provide therapy as a single-dose
anthelmintic against H. bakeri, we treated H. bakeri-infected mice
with Bt spore-crystal lysates expressing or not expressing (placebo
control) Cry5B. When the bacterium Bt sporulates, it produces
spores, large crystal protein-containing inclusions, and lysate
produced when the mother cell that gives rise to the spore and
crystal lyses upon completion of sporulation. Bt spore-crystal
lysates (SCLs) from many Bt strains, including Bt kurstaki HD1 that
targets caterpillars (Lepidoptera), have been extensively tested
against mammals (including humans) and found to be non-
pathogenic [15,26,27]. We transformed a crystal protein-minus
HD1 strain with a Cry5B-expressing plasmid. Twenty mice were
infected with H. bakeri larvae. Fifteen days post-infection (P.I.), we
delivered into each mouse per os either a single 0.1 mL dose of
Cry5B-containing HD1 SCLs (715 nmoles/kg or 100 mg/kg of
Cry5B) or, as a placebo control, a single 0.1 mL dose of spore
lysates (SLs, crystal-minus) from the parent, untransformed HD1
strain. Beginning the day before treatment (day 14 P.I. or day -1
treatment), and then continuing every other day (day 1, 3, 5 post-
treatment), we collected fecal samples from each mouse to
measure parasite progeny production (eggs/gram of feces). Five
days after treatment (day 20 P.I.), the mice were euthanized and
the total number of parasites present in the small intestine tallied.
With regards to progeny production, we found that on the day
prior to treatment, the parasites in both groups of mice (placebo
treated and Cry5B treated) were producing statistically indistin-
guishable amounts of eggs (Figure 1, Table 1). At days 1, 3, and 5
post-treatment, the placebo group showed no reduction in egg
production, consistent with the hypothesis that the parent Bt strain
alone has no effect on the parasites. In contrast, a rapid and
remarkable reduction in egg production took place in the Cry5B-
treated animals, resulting in a 95%, 99%, and 98% reduction on
days 1, 3, and 5 post-treatment respectively (Figure 1, Table 1).
With regards to parasite clearance, we found that the single dose of
Cry5B achieved a remarkable therapeutic effect, clearing away
67% of the parasites relative to placebo control (Figure 2A,
Table 2). Thus, a single dose of Cry5B has strong effects on
parasite reproduction and the ability of parasites to maintain an
infection.
The reduction in fecal egg count (.97%) was much larger than
would be expected from the final mouse worm burden of the SCL-
treated animals (67% cleared). There are at least two possible
explanations for this—either the treatment was affecting the status
of the worms so that any worms left behind were severely
compromised in health or the treatment was preferentially
eliminating female over male parasites. To distinguish between
Figure 1. Effects of Cry5B on egg production in Heligmoso-
moides bakeri infected mice. Shown are the average eggs/gram of
feces/mouse for both placebo (n=10) and Cry5B HD1-(n=10) treated
groups the day before treatment (21) and then every other day
thereafter until the animals were euthanized on day 5 post-treatment.
doi:10.1371/journal.pntd.0000614.g001
Table 1. Fecal egg counts in Cry5B HD1 experiment.
Day number relative to treatment
211 3 5
Placebo 34556457 34636381 43036439 41306766
Cry5B (715 nM/kg) 26986282 170630 43617 100633
Reduction relative to placebo N/A 95.1% 99.0% 97.6%
Numbers shown are eggs/gram of feces/mouse averaged for all 10 mice in each
group 6 standard error of the mean (sem).
doi:10.1371/journal.pntd.0000614.t001
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present in placebo versus Cry5B treated controls during the
counting of the worm burdens. In placebo treated mice we found
that there were 35.365.9 (standard error of the mean, or sem)
females while in the Cry5B treated mice there were 7.862.3 (sem)
females per mouse intestine. Thus, there was a 78% reduction in
the number of females present. This drop, although greater than
that for males (51% reduction), does not seem sufficient to account
for the observed .97% drop in egg production seen. These data
suggest that the parasites that remained in the intestine were
severely compromised in health.
We also determined if this capacity to clear an infection was
dependent upon a particular Bt strain. We performed a similar
curative experiment, measuring intestinal worm burdens after
treatment, using the Bt strain 4Q7 (derived from Bt israelensis,
which targets Diptera) either transformed with the Cry5B-
expressing plasmid or untransformed. Fourteen mice were infected
with H. bakeri larvae, and fifteen days P.I. a single dose of 0.1 mL
Cry5B-containing 4Q7 SCLs or 0.1 mL 4Q7 SLs (crystal-minus)
were delivered per os. The dose delivered per mouse was
644 nmoles/kg (90 mg/kg). We found a similar therapeutic effect
as above—71% of the parasites were cleared relative to placebo
control (Figure 2B, Table 2). We note that in this experiment the
total number of parasites present in the small intestine in placebo
control animals was greater than in the first experiment. The
variability appears to be due to relative infectivity of different
batches of L3 parasite larvae. These data demonstrate that,
regardless of parent Bt strain and of the initial parasite load, a
similar single dose of Cry5B is able to achieve comparable
therapeutic effect.
Cry5B compares highly favorably versus known
anthelmintics
These results are significant when the relative efficacy of Cry5B
is compared to other standard anthelmintic treatments. Published
reports, employing a treatment timeline against H. bakeri parasites
that is similar to our own, show that levamisole (10 mg/kg or
49 mmoles/kg delivered on day 12 P.I.) effected a 90% reduction
in worm burdens and ivermectin (5 mg/kg or 5.7 mmoles/kg) or
pyrantel (50 mg/kg or 84 mmoles/kg) or piperazine (4000 mg/kg
or 46 mmoles/kg) delivered on day 18 P.I. effected an 87%, 98%,
and 34% reduction in worm burdens respectively ([28,29].
Another study showed that 2.9 mmoles/kg of ivermectin delivered
on day 10 P.I. effected ,70% reduction in H. bakeri worm burdens
[30]. We could not find comparable studies with H. bakeri and
benzimidazoles, although we did find that mebendazole delivered
for 7 consecutive days, starting day 9 P.I. at 22 mg/kg/dose or
75 mmoles/kg/dose, achieved an 84% reduction in worm burdens
[31]. Benzimidazoles (including albendazole) in general seem to be
less active against H. bakeri [32]. Therefore, our single dose of
,700 nmoles/kg (which is the highest dose we can currently
pipette with SCLs) that achieved ,70% reduction in worm
burdens is 70X, 4–8X, 120X and 65,000X lower than the doses of
levamisole, ivermectin, pyrantel, and piperazine used in the above
studies.
Figure 2. Effects of Cry5B on intestinal worm burdens in Heligmosomoides bakeri infected in mice. A. Shown are the intestinal worm
burdens in placebo (HD1 SL) and Cry5B (HD1 SCL) treated mice (n=10 each group). Infected mice were given a single dose of 715 nmoles/kg
(100 mg/kg) Cry5B on day 15 P.I. and intestinal worm burdens assessed on day 20 P.I. The worm burdens in each mouse are indicated with a separate
symbol. Long horizontal bars represent mean worm burdens; smaller bars indicate sem (standard error of the mean). B. Shown are the intestinal
worm burdens in placebo (4Q7 SL) and Cry5B (4Q7 SCL) treated mice (n=7 per group). Mice were given a single dose of 644 nmoles/kg (90 mg/kg)
Cry5B on day 15 P.I. and intestinal worm burdens assessed on day 20 P.I. ** P,0.01, *** P,0.001.
doi:10.1371/journal.pntd.0000614.g002
Table 2. Worm burdens in Cry5B treatment experiments.
Group
(no. of mice)
Intestinal worm burden
(mean 6 sem)
% Reduction relative
to placebo
HD1 placebo (10) 59.1611.1 NA
Cry5B (10) 19.463.6 67.2
4Q7 placebo (7) 169.1614.0 NA
Cry5B (7) 48.1615.3 71.5
placebo: crystal-deficient HD1 or 4Q7 strain; Cry5B: the corresponding strain
transformed with a Cry5B-expressing plasmid. Cry5B dosage: 715 nm/kg (HD1)
or 644 nm/kg (4Q7).
sem = standard error of the mean.
NA = not applicable.
doi:10.1371/journal.pntd.0000614.t002
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relative to known anthelmintics is excellent. To directly compare
our results to a known anthelmintic using the same treatment
conditions, we performed curative experiments using the newest
human anthelmintic and the only one taken to human clinical
trials in the past thirty years, tribendimidine. We performed dose-
dependent curative assays with tribendimidine against H. bakeri
infections, finding an estimate dose of ,1 mg/kg or 2.2 mmoles/
kg tribendimidine to give a curative effect similar to
,700 nmoles/kg Cry5B (Figure 3, Table 3). Based on this
comparison, Cry5B is at least as good as tribendimidine at curing
H. bakeri infections and in fact appears to be ,2–3 fold superior.
Cry5B is rapidly digested in simulated gastric fluids
These data indicate that Cry5B is an excellent anthelmintic
when delivered at a single dose. However, Cry proteins are
thought to be digested rapidly in the mammalian digestive tract,
most notably by the acidic stomach [33]. If so, then it is possible
that the dose of Cry protein reaching the parasites might have
been very small.
To determine how well Cry5B would survive the mammalian
stomach, we incubated Cry5B HD1-derived SCLs in simulated
gastric fluids. We find that Cry5B is almost completely digested in
this environment within four minutes (Figure 4). These data
suggest that very little Cry5B is actually reaching the parasites.
Discussion
Our study demonstrates that the Bt Cry protein Cry5B is an
excellent anthelmintic in vivo against a natural and chronic
intestinal roundworm infection in mice, namely H. bakeri. Cry5B
is able to achieve significant reductions in parasite egg production
(,98%) and intestinal worm burdens (,70%) following a single
dose delivered per os at ,700 nmoles/kg. This therapeutic effect,
on a mole-by-mole basis, is on par with or superior to those of
other anthelmintics commonly used in human therapy. Although
this level of efficacy may seem surprising at first glance, upon
deeper reflection it is not. Cry proteins, although they only attack
the gut cells of invertebrates, are pore-forming toxins (PFTs; [34]).
PFTs are the single most common virulence factors made by
pathogenic bacteria and are also used by our immune system to
combat pathogens [35,36]. PFTs are potent weapons and the
consequences of their attack on the integrity of the plasma
membrane are great. In combination with previous data showing
that Cry5B is also able to cure A. ceylanicum infections in hamsters
[18], we have now demonstrated in vivo anthelmintic activity of
Cry5B against two very different parasitic nematodes (one a blood
feeder, the other not) in two different mammalian hosts. Taken
together, along with the fact that Cry5B is active against
Nippostrongylus brasiliensis larvae, against Haemonchus contortus larvae
in vitro, against a phylogenetically wide range of free-living
nematodes, and against the plant-parasitic nematode Meloidogyne
incognita [16,17,37], our data indicate that Cry5B has very broad
anti-nematode activity and that Cry5B has superb potential in
human anthelmintic therapy.
Figure 3. Effects of tribendimidine on Heligmosomoides bakeri
infections in mice. Shown are the intestinal worm burdens in placebo
(20 mM citrate buffer pH 7.3) and for various doses of tribendimidine.
Data are plotted as in Figure 1. Infected mice (n=6/group except n=5
placebo) were given a single dose of tribendimidine on day 15 P.I. and
intestinal worm burdens assessed on day 20 P.I. **P,0.01, ***P,0.001
relative to placebo control. Conversion to molar amounts is as follows:
0.125, 0.5, and 2 mg/kg are equivalent to 0.28, 1.1, and 4.4 mmoles/kg
respectively.
doi:10.1371/journal.pntd.0000614.g003
Table 3. Worm burdens in tribendimidine treatment
experiment.
Group (n=number
of mice)
Intestinal worm burden
(mean 6 sem)
% Reduction relative
to placebo
Placebo (n=5) 83.868.7 N/A
0.125 mg/kg trib (n=6) 53.269.3 36.5
0.5 mg/kg trib (n=6) 33.0610.7 60.6
2 mg/kg trib (n=6) 13.469.1 84.0
sem = standard error of the mean.
N/A not applicable.
trib = tribendimidine.
doi:10.1371/journal.pntd.0000614.t003
Figure 4. Behavior of Cry5B in simulated gastric fluids. Left lane,
markers. Next three lanes: Cry5B loading control 10, 1, and 0.1 mg Cry5B
in HD1 SCLs. Next two lanes: Cry5B (10 mg/lane) SCLs in water
incubated for 0 or 2 h at 37u. No degradation is seen. Next seven
lanes: Cry5B (10 mg/lane) SCLs incubated in simulated gastric fluid (SGF)
for the time indicated (in minutes). Cry5B has nearly disappeared after
four minutes. Right two lanes: simulated gastric fluids (no Cry5B)
incubated for 0 and 2 h at 37u to demonstrate where pepsin runs on
the gel. 8% SDS polyacrylamide gel stained with Coomassie blue.
doi:10.1371/journal.pntd.0000614.g004
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Cry5B to other natural product anthelmintics. No recently
investigated biological treatments against H. bakeri demonstrate
comparable in vivo efficacy using single-dose regimens. Many of
these natural compounds, such as the extract of Embelia schimperi,
nitazoxanide, santonin, and Myrsine Africana, showed only small
reductions in intestinal worm burden as a single dose, with
efficacies of 30%, 21%, 18%, and 10%, respectively [29,38,39]. A
single dose of 500 mg/kg of Albizia anthelmintica, not only revealed
low efficacy, with a total worm burden reduction of only 3–23%,
but also displayed significant toxicity [28]. Even the macrolactam
N-methylfluvirucin, delivered at a daily dose of 50 mg/kg over 3
days, effected only a 42% reduction in total worm burden [40].
While other compounds were more efficient, they required
extremely high doses and/or multiple-day dosing regimens. These
included a daily treatment of ethanol extract of Canthium manni
(Rubiaceae) at 5600 mg/kg, which showed a 75% decrease in
fecal egg count and 84% reduction in worm burden with 7 days of
treatment [31]. A 600 mg/kg treatment with extract of stem bark
of Sacoglottis gabonensis was extremely effective, but exceedingly
toxic, with mice showing signs such as depression, drowsiness,
unsteady gait and paralysis of the hind limbs, dyspnoea, coma and
death apparent within 1–2 min following intraperitoneal injection
[41]. Perhaps the most promising of other natural treatments is
papaya latex. A single-dose administration of papaya latex at 8 g/
kg achieved an efficacy of 84.5%, with fecal egg count reductions
of 93.3% [42]. Mice treated daily over 7 days with 133 nmoles of
papaya latex showed a decrease in fecal egg count of 87–97% and
a 92% reduction of worm burden [43]. In general, few of the
natural compounds tested above proved to be practical treatments
due to dosing and toxicity issues.
It is clear that Cry5B has great promise as an effective, safe, and
much-needed addition to anthelmintic therapy. The vertebrate
and human safety profiles of Cry proteins are outstanding—Cry
proteins as insecticides are used around the world on a large-scale
in organic farming, in aerial spray campaigns, and in vector
(mosquito, black fly) control programs and have even been
approved for expression in transgenic foods such as corn, potatoes,
and rice [14,44]. Although Cry5B has not been studied in this
regard, it is a member of the same family of three-domain Cry
proteins expressed in transgenic crops and used in all these spray
programs and thus is predicted to have the same safety profile.
Indeed, extensive research from our laboratory has confirmed that
the receptor Cry5B needs to bind to in order to intoxicate
nematodes is an invertebrate-specific glycan (carbohydrate) [45].
It is interesting to note that, although Cry5B has comparable if
not superior activity against H. bakeri on a mole-by-mole basis with
other anthelmintics, it is likely that only tiny amounts of the
protein being delivered per os in our experiments are reaching the
parasites. In four minutes, virtually all Cry5B is degraded in
simulated gastric fluids. These experiments suggest that a simple
enteric coating to protect Cry proteins against the stomach while
releasing it in the small or large intestines might greatly increase
the efficacy of Cry proteins. These data thus emphasize the
importance of formulation in the next stage in the evolution of Cry
protein anthelmintic development and suggest that such a
formulation has the potential to reveal an anthelmintic with
therapeutic properties comparable or superior to those currently in
use.
Supporting Information
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